Small Molecule Inhibitors of Human Papillomavirus: A Review of Research from 1997 to 2021.

Autor:	Duncan CL; School of Molecular and Life Sciences, Curtin University, GPO Box U1987, Perth, WA, 6845, Australia., Gunosewoyo H; Curtin Medical School, Curtin University, GPO Box U1987, Perth, WA, 6845, Australia., Mocerino M; School of Molecular and Life Sciences, Curtin University, GPO Box U1987, Perth, WA, 6845, Australia., Payne AD; School of Molecular and Life Sciences, Curtin University, GPO Box U1987, Perth, WA, 6845, Australia.
Jazyk:	angličtina
Zdroj:	Current medicinal chemistry [Curr Med Chem] 2024; Vol. 31 (33), pp. 5308-5350.
DOI:	10.2174/0929867331666230713165407
Abstrakt:	Human papillomavirus (HPV) infections are the cause of warts, lesions and cancer, with different types of HPV causing different symptoms. HPV infections are the primary cause of cervical cancer. There are over 220 different types of HPV, and only nine of these can currently be vaccinated. There is a need to treat these viral infections without just treating the symptoms of the infection, as is currently the main method. There is a wide range of small molecules that have been used to inhibit various stages of the HPV infectious cycle. This review examined 132 small molecules from 121 studies that specifically target aspects of HPV infections. HPV DNA encodes for six early genes (E1 to E7, skipping E3) and two late genes (L1 and L2). According to the results, these targets for small molecule inhibitors fall into three categories: those targeting E1 and E2, targeting E6 and E7 and, finally, targeting L1 and L2. Inhibitors of E6 and E7 are the most widely studied targets, with the majority of HPV inhibition in this area. While compounds targeting both E1/E2 and E6/E7 have made it to clinical trials, there has been no significant advancement on the topic. (Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu